UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2024
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip code) | |||||||
(206 ) 333-2001
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On October 29, 2024, Nautilus Biotechnology, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |||||||
| 104 | Cover page Interactive Data File (embedded with the Inline XBRL document) | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 29, 2024
| NAUTILUS BIOTECHNOLOGY, INC. | ||||||||
| By: | /s/ Sujal Patel | |||||||
| Name: | Sujal Patel | |||||||
| Title: | Chief Executive Officer | |||||||
Exhibit 99.1
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
SEATTLE, WA, October 29, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024.
“I’m excited about the expanding opportunity I see for proteomics and am pleased with the progress we’re making as a business,” said Sujal Patel, CEO of Nautilus. “We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what’s currently available. It is becoming ever more apparent that they understand how important the single-molecule, intact protein analysis to be enabled by the Nautilus platform will be to their explorations of the proteome.”
Third Quarter 2024 Financial Results
Operating expenses were $19.1 million for the third quarter of 2024, flat compared to the corresponding prior year period. Overall personnel cost increased during the third quarter of 2024 as compared to the corresponding prior year period offset by a one-time reduction to accrued incentive compensation in the third quarter of 2024.
Net loss was $16.4 million for the third quarter of 2024, as compared to a net loss of $15.9 million for the corresponding prior year period.
Cash, cash equivalents, and investments were $221.2 million as of September 30, 2024.
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the third quarter 2024 financial results, business developments and outlook before market open on Tuesday, October 29, 2024, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus’ product platform and full commercial availability, the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk
1
Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
2
Nautilus Biotechnology, Inc. Condensed Consolidated Balance Sheets As of September 30, 2024 and December 31, 2023 (Unaudited) | ||
| (in thousands, except share and per share amounts) | September 30, 2024 | December 31, 2023 | |||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 4,409 | $ | 19,397 | |||||||
| Short-term investments | 136,200 | 154,021 | |||||||||
| Prepaid expenses and other current assets | 3,596 | 3,419 | |||||||||
| Total current assets | 144,205 | 176,837 | |||||||||
| Property and equipment, net | 4,324 | 4,267 | |||||||||
| Operating lease right-of-use assets | 29,377 | 32,634 | |||||||||
| Long-term investments | 80,618 | 90,647 | |||||||||
| Other long-term assets | 1,180 | 1,180 | |||||||||
| Total assets | $ | 259,704 | $ | 305,565 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,487 | $ | 1,639 | |||||||
| Accrued expenses and other liabilities | 3,216 | 3,945 | |||||||||
| Current portion of operating lease liabilities | 3,959 | 3,538 | |||||||||
| Total current liabilities | 8,662 | 9,122 | |||||||||
| Operating lease liabilities, net of current portion | 27,608 | 31,090 | |||||||||
| Total liabilities | 36,270 | 40,212 | |||||||||
| Stockholders' equity: | |||||||||||
| Preferred stock | — | — | |||||||||
| Common stock | 13 | 13 | |||||||||
| Additional paid-in capital | 478,115 | 467,834 | |||||||||
| Accumulated other comprehensive income (loss) | 731 | (255) | |||||||||
| Accumulated deficit | (255,425) | (202,239) | |||||||||
| Total stockholders’ equity | 223,434 | 265,353 | |||||||||
| Total liabilities and stockholders' equity | $ | 259,704 | $ | 305,565 | |||||||
3
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three and Nine Months Ended September 30, 2024 and 2023 (Unaudited) | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (in thousands, except share and per share data) | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Research and development | $ | 12,288 | $ | 11,996 | $ | 37,654 | $ | 34,785 | |||||||||||||||
| General and administrative | 6,812 | 7,079 | 23,842 | 21,366 | |||||||||||||||||||
| Total operating expenses | 19,100 | 19,075 | 61,496 | 56,151 | |||||||||||||||||||
| Other income (expense) | |||||||||||||||||||||||
| Interest income | 2,674 | 3,197 | 8,349 | 9,517 | |||||||||||||||||||
| Other expense | (20) | — | (39) | (17) | |||||||||||||||||||
| Total other income | $ | 2,654 | $ | 3,197 | $ | 8,310 | $ | 9,500 | |||||||||||||||
| Net loss | $ | (16,446) | $ | (15,878) | $ | (53,186) | $ | (46,651) | |||||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.13) | $ | (0.13) | $ | (0.42) | $ | (0.37) | |||||||||||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 125,452,572 | 124,933,837 | 125,302,440 | 124,896,975 | |||||||||||||||||||
4
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Cash Flows Nine Months Ended September 30, 2024 and 2023 (Unaudited) | ||
| Nine Months Ended September 30, | |||||||||||
| (in thousands) | 2024 | 2023 | |||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (53,186) | $ | (46,651) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||||||||
| Stock-based compensation expense | 9,577 | 9,064 | |||||||||
| Amortization of operating lease right-of-use assets | 3,257 | 2,821 | |||||||||
| Depreciation | 1,543 | 1,294 | |||||||||
| Amortization (accretion) of premium (discount) on securities, net | (2,176) | (2,040) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Prepaid expenses and other assets | (26) | (878) | |||||||||
| Accounts payable | (35) | 22 | |||||||||
| Accrued expenses and other liabilities | (729) | 757 | |||||||||
| Operating lease liabilities | (3,061) | (2,200) | |||||||||
| Net cash used in operating activities | (44,836) | (37,811) | |||||||||
| Cash flows from investing activities | |||||||||||
| Proceeds from maturities of securities | 90,410 | 51,249 | |||||||||
| Purchases of securities | (59,398) | (51,895) | |||||||||
| Purchases of property and equipment | (1,868) | (2,029) | |||||||||
| Net cash provided by (used in) investing activities | 29,144 | (2,675) | |||||||||
| Cash flows from financing activities | |||||||||||
| Proceeds from exercise of stock options | 415 | 23 | |||||||||
| Proceeds from issuance of common stock under employee stock purchase plan | 289 | 92 | |||||||||
| Net cash provided by financing activities | 704 | 115 | |||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | (14,988) | (40,371) | |||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 20,399 | 115,477 | |||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 5,411 | $ | 75,106 | |||||||
5